本文選題：益脾養(yǎng)肝方 + 原發(fā)性肝癌��； 參考：《遼寧中醫(yī)雜志》2017年05期

【摘要】：目的:觀察和評價益脾養(yǎng)肝方聯(lián)合TACE和3DCRT治療原發(fā)性肝癌的臨床療效。方法:51例原發(fā)性肝癌患者隨機分為治療組(26例),給予中藥益脾養(yǎng)肝方聯(lián)合TACE及3DCRT治療;對照組(25例),給予TACE和3DCRT治療。兩組療程35~42 d(根據(jù)3DCRT治療時間而變化)。觀察和比較兩組病例在治療前后中醫(yī)證候、實體瘤大小、細(xì)胞免疫功能、肝功能、生存率等方面的相關(guān)指標(biāo)并進(jìn)行統(tǒng)計分析。結(jié)果:經(jīng)治療后,治療組中醫(yī)療效總有效率88.0%,對照組中醫(yī)療效總有效率32.0%,兩組比較有顯著性差異(P0.05)。治療組在中醫(yī)證候改善,CD3+、CD3+CD4+變化,降低ALT、AST等方面優(yōu)于對照組,差異有統(tǒng)計學(xué)意義(P0.05)。治療組在實體瘤大小改變、生存率等方面均優(yōu)于對照組,但差異無統(tǒng)計學(xué)意義(P0.05㖞。結(jié)論:益脾養(yǎng)肝方聯(lián)合TACE和3DCRT治療原發(fā)性肝癌,可以明顯改善患者臨床癥狀、改善生化指標(biāo)、提高患者生活質(zhì)量,且安全可靠。
[Abstract]:Objective: to observe and evaluate the clinical effect of Yipi Yanggan recipe combined with TACE and 3DCRT in the treatment of primary liver cancer. Methods Fifty-one patients with primary liver cancer were randomly divided into treatment group (n = 26) and control group (n = 25) treated with TACE and 3DCRT. The course of treatment in both groups was 35 days and 42 days (according to the time of 3DCRT treatment). The indexes of TCM syndromes, tumor size, cellular immune function, liver function and survival rate before and after treatment were observed and compared. Results: after treatment, the total effective rate of TCM was 88.0 in the treatment group and 32.0 in the control group. The difference between the two groups was significant (P 0.05). The treatment group was superior to the control group in improving the changes of CD3 + CD3 CD4 and decreasing alt in TCM syndromes. The difference was statistically significant (P 0.05). The size of solid tumor and survival rate in the treatment group were better than those in the control group, but the difference was not statistically significant (P 0.05). Conclusion: Yipi Yanggan recipe combined with TACE and 3DCRT can obviously improve the clinical symptoms, improve biochemical indexes, improve the quality of life of patients, and is safe and reliable.
【作者單位】： 陜西中醫(yī)藥大學(xué)附屬醫(yī)院;
【基金】：國家自然科學(xué)基金(81603612) 陜西省科技廳(2012SF2-11,2014K11-02-04-06,2016SF-234) 陜西省中醫(yī)藥管理局(15-JC009) 北京醫(yī)學(xué)獎勵基金會課題(YJHYXKYJJ-276)
【分類號】：R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前2條

1 周永強;易金玲;金獻(xiàn)測;黃珂靖;吳志勤;韓策;謝聰穎;;VMAT結(jié)合CRT治療胸上段食道癌的劑量學(xué)研究[J];中國醫(yī)學(xué)物理學(xué)雜志;2013年02期

2 ;[J];;年期

，

本文編號：1838783